Skip to content

Yukihiko Shirayama

3 papers in the library · 833 citations · publishing 2015-2020

Papers

Sort Most recent Most cited

Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1

Translational Psychiatry January 27, 2020 Kai Zhang, Chun Yang, Lijia Chang et al. 120 citations

In rodent models of depression, (R)-ketamine has greater potency and longer-lasting antidepressant effects than (S)-ketamine; however, the precise molecular mechanisms underlying the antidepressant actions of (R)-ketamine remain unknown. Using RNA-sequencing analysis, we identified novel molecular targets that contribute to the different antidepressant effects of the two enantiomers. Either...

Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine

The International Journal of Neuropsychopharmacology November 14, 2017 Yukihiko Shirayama, Kenji Hashimoto 113 citations

Background: (R)-Ketamine exhibits rapid and sustained antidepressant effects in animal models of depression. It is stereoselectively metabolized to (R)-norketamine and subsequently to (2R,6R)-hydroxynorketamine in the liver. The metabolism of ketamine to hydroxynorketamine was recently demonstrated to be essential for ketamine's antidepressant actions. However, no study has compared the...

R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects

Translational Psychiatry September 1, 2015 Chun Yang, Yukihiko Shirayama, J-C Zhang et al. 600 citations

Although the efficacy of racemate ketamine, a rapid onset and sustained antidepressant, for patients with treatment-resistant depression was a serendipitous finding, clinical use of ketamine is limited, due to psychotomimetic side effects and abuse liability. Behavioral and side-effect evaluation tests were applied to compare the two stereoisomers of ketamine. To elucidate their potential...